S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:YMTX

Yumanity Therapeutics Stock Forecast, Price & News

$1.82
-0.03 (-1.62%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.76
$1.95
50-Day Range
$1.82
$5.22
52-Week Range
$1.76
$22.70
Volume
74,315 shs
Average Volume
69,587 shs
Market Capitalization
$18.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.44
30 days | 90 days | 365 days | Advanced Chart
Receive YMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Yumanity Therapeutics logo

About Yumanity Therapeutics

Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA.

Headlines

Yumanity Therapeutics, Inc. (YMTX)
December 31, 2021 |  realmoney.thestreet.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:YMTX
Fax
N/A
Employees
45
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.90 million
Book Value
$21.54 per share

Profitability

Net Income
$-57.49 million
Net Margins
-605.00%
Pretax Margin
-605.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,020,000
Market Cap
$18.76 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/22/2022
Next Earnings (Estimated)
3/30/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.95 out of 5 stars

Medical Sector

636th out of 1,418 stocks

Pharmaceutical Preparations Industry

306th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Yumanity Therapeutics (NASDAQ:YMTX) Frequently Asked Questions

Is Yumanity Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Yumanity Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Yumanity Therapeutics stock.
View analyst ratings for Yumanity Therapeutics
or view top-rated stocks.

Are investors shorting Yumanity Therapeutics?

Yumanity Therapeutics saw a decline in short interest in the month of December. As of December 15th, there was short interest totaling 61,200 shares, a decline of 61.4% from the November 30th total of 158,400 shares. Based on an average daily trading volume, of 175,700 shares, the short-interest ratio is currently 0.3 days. Currently, 0.9% of the company's shares are sold short.
View Yumanity Therapeutics' Short Interest
.

When is Yumanity Therapeutics' next earnings date?

Yumanity Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Yumanity Therapeutics
.

How were Yumanity Therapeutics' earnings last quarter?

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.97) EPS for the quarter, topping the Zacks' consensus estimate of ($1.13) by $0.16. The business earned $1.64 million during the quarter, compared to analyst estimates of $1.93 million. Yumanity Therapeutics had a negative net margin of 605.00% and a negative trailing twelve-month return on equity of 147.18%.
View Yumanity Therapeutics' earnings history
.

What price target have analysts set for YMTX?

2 equities research analysts have issued 1-year price objectives for Yumanity Therapeutics' shares. Their forecasts range from $35.00 to $39.00. On average, they expect Yumanity Therapeutics' stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 1,933.0% from the stock's current price.
View analysts' price targets for Yumanity Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Yumanity Therapeutics' key executives?

Yumanity Therapeutics' management team includes the following people:
  • Richard Peters, President, CEO, Secretary, Treasurer & Director
  • Michael D. Wyzga, Chief Financial Officer & Senior Vice President
  • Ajay Verma, Executive VP, Head-Research & Development
  • Brigitte Robertson, Chief Medical Officer
  • Daniel Tardiff, Research Head

What is Yumanity Therapeutics' stock symbol?

Yumanity Therapeutics trades on the NASDAQ under the ticker symbol "YMTX."

How do I buy shares of Yumanity Therapeutics?

Shares of YMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Yumanity Therapeutics' stock price today?

One share of YMTX stock can currently be purchased for approximately $1.82.

How much money does Yumanity Therapeutics make?

Yumanity Therapeutics has a market capitalization of $18.76 million and generates $6.90 million in revenue each year.

How many employees does Yumanity Therapeutics have?

Yumanity Therapeutics employs 45 workers across the globe.

What is Yumanity Therapeutics' official website?

The official website for Yumanity Therapeutics is www.yumanity.com.

Where are Yumanity Therapeutics' headquarters?

Yumanity Therapeutics is headquartered at 40 GUEST STREET SUITE 4410, BOSTON MA, 02135.

How can I contact Yumanity Therapeutics?

Yumanity Therapeutics' mailing address is 40 GUEST STREET SUITE 4410, BOSTON MA, 02135. The company can be reached via phone at (617) 409-5300 or via email at [email protected].


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.